New brain cancer treatment targets tumour hypoxia to make radiotherapy work better

Omniox, Inc. is a biopharmaceutical company with a new protein-based platform (H-NOX) that has been engineered to make radiation therapy more effective for certain brain tumours. The lead H-NOX product (OMX-4.80) is being developed as an oxygen delivery carrier for reversing hypoxia in glioblastoma, the most common and aggressive primary brain tumor.

MedCity News